IDEXX Laboratories, Inc. $IDXX Shares Sold by Tidal Investments LLC

by · The Cerbat Gem

Tidal Investments LLC cut its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 50.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,109 shares of the company’s stock after selling 19,705 shares during the quarter. Tidal Investments LLC’s holdings in IDEXX Laboratories were worth $10,060,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the company. Aurora Investment Managers LLC. acquired a new stake in IDEXX Laboratories during the 2nd quarter valued at approximately $2,442,000. Elyxium Wealth LLC bought a new stake in shares of IDEXX Laboratories during the 4th quarter valued at about $3,666,459,000. Prospera Financial Services Inc acquired a new stake in shares of IDEXX Laboratories during the 4th quarter worth approximately $4,188,000. Axxcess Wealth Management LLC lifted its stake in IDEXX Laboratories by 312.3% in the fourth quarter. Axxcess Wealth Management LLC now owns 5,121 shares of the company’s stock valued at $3,465,000 after buying an additional 3,879 shares during the last quarter. Finally, Life Cycle Investment Partners Ltd acquired a new position in IDEXX Laboratories during the 4th quarter valued at about $47,915,000. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Down 0.4%

Shares of NASDAQ IDXX opened at $504.70 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $500.61 and a 12-month high of $769.98. The company has a quick ratio of 0.87, a current ratio of 1.17 and a debt-to-equity ratio of 0.19. The firm’s 50-day simple moving average is $555.59 and its 200 day simple moving average is $566.45. The company has a market cap of $39.76 billion, a price-to-earnings ratio of 35.49, a price-to-earnings-growth ratio of 2.70 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. The business had revenue of $1.22 billion during the quarter, compared to analyst estimates of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. On average, research analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have recently commented on IDXX shares. UBS Group raised their price target on IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Barclays cut their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a report on Tuesday, August 11th. Citigroup increased their price objective on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Finally, Weiss Ratings lowered shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, IDEXX Laboratories currently has an average rating of “Moderate Buy” and an average target price of $747.00.

Get Our Latest Report on IDEXX Laboratories

Insider Activity at IDEXX Laboratories

In other news, Director Lawrence D. Kingsley sold 2,203 shares of IDEXX Laboratories stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $532.08, for a total transaction of $1,172,172.24. Following the completion of the sale, the director owned 9,568 shares in the company, valued at $5,090,941.44. The trade was a 18.72% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.79% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc develops and provides diagnostic, information technology and veterinary practice-management products and services. The company primarily serves the companion animal, livestock and poultry, and water testing markets, helping customers detect, monitor and manage disease.

Its companion animal business includes in-house laboratory analyzers and consumables, reference laboratory services, diagnostic tests, veterinary software, digital imaging and related practice-management solutions.

Further Reading